← Atea Pharmaceuticals, Inc. (AVIR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Atea Pharmaceuticals, Inc. (AVIR)
Pharmaceutical Preparations · market cap $435M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
5
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Atea Pharmaceuticals (AVIR) is a small-cap antiviral-focused biotech with 56 employees and a $391M market cap, built around bemnifosbuvir (BEM), a nucleotide analogue in Phase 3 for COVID-19 and, in combination with ruzasvir (BEM/RZR), in Phase 3 for chronic hepatitis C. The company has burned through its revenue base since a $351M revenue year in 2021, posting ~$158M net losses in 2025 with only $79.3M cash remaining — roughly five months of runway — making near-term catalysts existential.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 3 · Bemnifosbuvir-Ruzasvirimp 9/10
- 2026-12-31Phase 3imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Bemnifosbuvir | Phase 2 | Chronic Hepatitis C Virus |
| Bemnifosbuvir (BEM) | Phase 3 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection) |
| Bemnifosbuvir-Ruzasvir | Phase 3 | HEPATITIS C VIRUS CHRONIC INFECTION |
| Bemnifosbuvir-Ruzasvir (BEM/RZR) | Phase 3 | HEPATITIS C VIRUS CHRONIC INFECTION |
| AT-527 | Phase 2 | Hepatitis C |
Price & technical context
3-month
+2.4%
6-month
-9.7%
12-month
+75.9%
52-wk range
$2.82–$6.15
vs 50-day MA
-1.9%
vs 200-day MA
+6.1%
Realized vol
50.4%
Max drawdown
-36.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AVIR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.